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Introduction
In advanced atherosclerotic lesions, smooth muscle cell 
(SMC) accumulation in the intima results from cell prolif-
eration and directed migration of SMCs from the media 
into the intima.1 These processes are regulated by various 
cytokines and chemokines through the activation of their 
receptors expressed on the cell surface of vascular SMCs.2 
In particular, the discovery of the prorenin receptor (PRR) 
expressed in vascular SMC has opened to a completely 
new scenario on the functional role of local renin–angio-
tensin–aldosterone system (RAAS) on atherosclerosis.3,4 
Pioneer studies have reported the presence of all the com-
ponents of the classical RAAS pathway in atherosclerotic 
lesions, implying its potential contribution on SMC accu-
mulation in the atherosclerotic plaque.5–8
PRR can be activated by either renin or prorenin;9 how-
ever, prorenin appears to be the most relevant agonist since 
its plasma concentrations are approximately tenfold higher 
than those of renin and the binding affinity is threefold 
higher than renin.10,11 The activation of PRR has been shown 
to drive cell cycle progression, DNA synthesis, ERK1(p44) 
and ERK2(p42) phosphorylation,12–14 and p38 MAP kinase/
HSP27 activation,15 all events associated with cell prolifera-
tion. Moreover, we have recently provided evidence that 
prorenin, through the activation of PRR, induces SMC 
migration.16 It is therefore conceivable to hypothesize that 
PRR activation may promote both SMCs proliferation and 
migration, pivotal features of atherogenesis.17
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Abstract
Background: In the present study, we investigated the potential effect of aliskiren on smooth muscle cell (SMC) 
migration in response to prorenin.
Methods: Cultured human SMCs were incubated with angiotensinogen (ANG) (1.5 × 10−7M) and increasing 
concentrations of aliskiren (10−6–10−5M). After 24 h, SMC migration was assessed by Boyden’s chamber chemotactic 
assay using prorenin as chemotactic factor (10−8M). The effect of aliskiren on RhoA and Rac activity was also determined 
by G-LISA assay and the lamellipodia formation by rhodamine–phalloidin staining. Changes in cell morphology were 
recorded in real-time using the iCelligence system.
Results: Aliskiren determined, at 10−5M, a significant inhibition of SMC migration induced by prorenin (−66.4±18.1%; p < 
0.05), while no significant effect was observed when PDGF-BB was utilized as chemotactic agent. Aliskiren also reduced 
Rac-GTP levels in response to prorenin (−54.2±5.4%) without affecting the RhoA-GTP levels. Finally, aliskiren inhibited 
both the lamellipodia formation and morphological changes induced by prorenin with no significant effect on PDGF-BB 
activity.
Conclusions: Taken together, we provide the first evidence of the inhibitory action of aliskiren on SMC migration 
induced by prorenin.
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Aliskiren represents the first direct renin inhibitor to be 
approved for clinical use in hypertension that blocks the 
RAAS at its point of origin,18,19 the renin–ANG interaction, 
thus preventing the conversion of angiotensinogen (ANG) 
to angiotensin I and interrupting the RAAS cascade. The 
renin inhibition by aliskiren determines a significant 
increase of renin and prorenin plasma concentrations,20 and 
thus potentially the activity of PRR in vascular SMCs.
From the crystal structure modeling and the in vitro 
results conducted with cells overexpressing PRR, it was 
demonstrated that aliskiren does not interfere with the 
binding of renin and prorenin to the PRR.13,21 However, in 
a model of hypertensive diabetic renal damage, renin inhi-
bition with aliskiren suppressed renal gene expression of 
the PRR and its target genes transforming growth factor-β 
(TGF-β) and type I collagen.22 A similar inhibitory effect 
of aliskiren on PRR has been observed in human aortic 
SMCs incubated with both prorenin and ANG.23 Such 
effect determined a significant inhibition of the transcrip-
tion of three genes, previously shown to be regulated by 
prorenin, such as TGF-β, type I collagen and plasminogen 
activator inhibitor-1 (PAI-1).3,24 Thus, aliskiren inhibits the 
in vivo RAAS activity by binding to the active site of cir-
culating renin or the unmasked catalytic site of prorenin 
bound to PRR and by reducing the PRR expression.4,22,23 
Although the patho-physiological relevance of the PRR 
down-regulation by aliskiren still needs to be fully eluci-
dated, results from in vivo experimental studies suggest 
that, to some extent, the anti-atherosclerotic properties of 
aliskiren are independent from the hypotension effect.25–28
Based on these premises, in the present study we tested the 
hypothesis that aliskiren may interfere with the prorenin-
dependent chemotactic effect on human aortic SMCs.
Material and methods
Cell culture
Human aortic SMCs were purchased from PromoCell 
and cultured in Smooth Muscle Cell Growth Medium 2 
supplemented with 5%FCS, 0.5 ng/mL of epidermal 
growth factor, 2 ng/mL of basic fibroblast growth factor, 
and 5 µg/mL of insulin. SMCs were utilized between pas-
sage 5 and 9. ANG and prorenin were purchased from 
Vinci-Biochem.
Experimental protocols
For the determination of cell migration, SMCs were seeded 
in complete medium at the density of 2 × 105 SMCs per 35 
mm petri dish. After 24 h, cells were incubated in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 0.4% FCS, 
ANG (1.5 × 10−7M) and increasing concentrations of 
aliskiren (10−6–10−5M). After an additional 24 h, SMCs 
were harvested by trypsinization, resuspended in their 
conditioned media and the migration determined by 
Boyden’s chamber chemotactic assay with prorenin 
(10−8M) or platelet-derived growth factor-BB (PDGF-BB) 
(10−9M) as chemotactic agents for 6–8 h. Under the same 
experimental conditions, the lamellipodia formation were 
assessed by rhodamine-phalloidin staining after 1 h stimu-
lation, while for G-LISA assay cells were stimulated for 10 
minutes. Finally, changes of cell morphology were moni-
tored every minute for 6 h after the addition of prorenin or 
PDGF-BB by iCelligence system.
Cell migration assay
The Boyden chamber and the polycarbonate membrane were 
purchased from Biomap (Agrate Brianza, Milan Italy). The 
membranes were coated with a 0.1 mg/mL of type I collagen 
solution (PureCol®, Nutacon BV, Leimuiden, The 
Netherlands) in 0.1M acetic acid at 37°C. The lower com-
partments of the wells of a modified Boyden chamber were 
filled (in triplicate) with DMEM containing 0.4% FCS in the 
absence or presence of prorenin or PDGF-BB, whereas the 
upper compartments were filled with SMCs suspensions 
containing 106 cells/mL. The cells were resuspended with 
their conditioned media containing ANG and increasing con-
centrations of aliskiren. The chamber was incubated at 37°C 
for 6 h. The membrane was then carefully removed. Adherent 
SMCs on the top were eliminated and the membrane was 
stained with the Diff-Quik staining set (Biomap, Agrate 
Brianza, Milan Italy). The number of transmigrated cells was 
counted in four random high-power fields (HPFs) under high 
magnification (objective lens 20×).29
Cytoskeleton staining
Cells were fixed in 4% paraformaldehyde at room tem-
perature for 10 min, permeabilized in 0.1% Triton X-100 
in phosphate-buffered saline for 15 min, and incubated 
with rhodamine-phalloidin (Sigma Aldrich, Milan, Italy). 
Cytoskeleton staining of cells was analyzed using a fluo-
rescence microscope (Axiovert M220; Zeiss Instruments).
Real-time monitoring of cell morphology using 
the iCELLigence system
The iCELLigence system (ACEA Biosciences Inc, San 
Diego, CA, USA) monitors cellular events in real time by 
recording the electrical impedance that is correlated with 
cell number, morphology and viability in a given culture 
well. For analyzing SMCs morphology, 40.000 cells/well 
were plated into the E-Plate L8, and the extent of cell spread-
ing was monitored every minute for 6 h with iCELLigence. 
The assay system expresses impedance in arbitrary cell 
index units (Rn − Rb)/4.6, where Rn is the cell–electrode 
impedance of the well when it contains cells and Rb is the 
background impedance of the well with the media alone.
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G-LISA assay for Rac and RhoA
The intracellular amount of Rac-GTP and RhoA-GTP 
were determined by using the G-LISA assay according to 
the manufacturer’s instruction (Cytoskeleton Inc, Denver, 
CO, USA).30
Statistical analysis
All data shown are representative of at least three replicate 
experiments. Data are expressed as mean±SD. Statistical 
analyses were performed using either the unpaired stu-
dent’s t test or 1-way ANOVA as appropriate; p values 
<0.05 were considered significant.
Results
In a first series of experiments, the effect of aliskiren on 
SMC migration was determined by Boyden’s chamber 
chemotactic assay. As previously reported,16 prorenin 
induced SMC migration (2.2±0.3 fold; p < 0.05) and the 
pre-incubation with 10−5M aliskiren for 24 h determined a 
significant inhibition of the chemotactic effect 
(−66.4±18.1%) (Figure 1). The prorenin-mediated SMC 
migration has been shown to be associated with the acti-
vation of both RhoA and Rac small GTPase proteins.16 
Thus the effect of aliskiren on the intracellular levels of 
Rac-GTP and RhoA-GTP was investigated by G-LISA 
assay. As shown in Figure 2, prorenin increased both 
RhoA-GTP and Rac-GTP levels by 39.0±1.4% and 
38.0±5.0%, respectively. The pre-incubation with 10−5M 
aliskiren inhibited the activation of Rac (−54.2±5.4%; p < 
0.05) while no effect was observed on RhoA-GTP levels 
(Figure 2).
In order to investigate whether the effect of aliskiren on 
SMC migration was specific to the prorenin stimulation, a 
series of Boyden’s chamber chemotactic assays using 
PDGF-BB as chemotactic agent was performed. SMCs 
were incubated for 24 h in DMEM containing 0.4%FCS 
and ANG in the presence or absence of increasing concen-
trations of aliskiren and then divided in two aliquots one 
for the migration towards prorenin and one towards 
PDGF-BB. Interestingly, aliskiren significantly affected 
the SMC migration induced by prorenin and no effect was 
observed with PDGF-BB (Figure 3). These data suggest 
that aliskiren selectively interferes with the prorenin 
mediated chemotactic action potentially by inhibiting Rac 
activation.
The effect of aliskiren on lamellipodia formation was 
examined by rhodamine-phalloidin staining of filamen-
tous actin (F-actin). After 1 h stimulation of SMCs with 
prorenin or PDGF-BB, a significant redistribution of 
F-actin was observed, resulting in the production of lamel-
lipodia and membrane protrusions (Figure 4). The pre-
incubation of 10−5M aliskiren prior cell stimulation, 
significantly affected the lamellipodia formation in 
response to prorenin while no effect was observed with 
PDGF-BB (Figure 4).
In order to better define the effect of aliskiren on cell 
morphology a real-time recording iCelligence system 
was utilized. The major advantages of this system is that 
the changes in cell morphology are monitored in real 
time and reported as average of 80.000 cells. As shown in 
Figure 5, prorenin induced significant changes in cell 
morphology as indicated by an increased cell index dur-
ing the first 3 h of stimulation reaching a plateau that was 
sustained up to 6 h. The presence of 10−5M aliskiren sig-
nificantly reduces the cell index values by approximately 
40% during all the duration of the recorded time. 
Differently from prorenin, PDGF-BB induced a strong 
and transient increase of cell index with a peak at 1h and 
the presence of aliskiren did not affect this response. 
Taken together, aliskiren significantly affected the SMC 
Figure 1. Aliskiren inhibits human SMC migration in response 
to prorenin. Human SMCs were cultured for 24 h in Smooth 
Muscle Cell Growth Medium 2 (50.000 cells per well/48 well 
tray). After 24 h, medium was changed with DMEM/0.4%FCS, 
ANG (1.5 × 10−7M) in the presence or absence of aliskiren 
(10−6M, 5 × 10−6M, and 10−5M). After 24 h, cells were harvested by 
trypsinization and the migration measured by Boyden’s chamber 
chemotactic assay by using prorenin (10−8M) as chemotactic 
agent. (a) Representative images of migrated SMCs stained with 
the Diff-Quik staining kit. (b) The number of transmigrated cells 
was counted in four random high-power fields (HPFs) under high 
magnification (objective lens 20×). Basal indicates cells incubated 
in DMEM/0.4%FCS and ANG (1.5 × 10−7M) and not stimulated 
with prorenin. †p < 0.05 prorenin vs. basal; *p < 0.05 aliskiren 
vs. prorenin. The results are representative of five independent 
experiments.
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migration induced by prorenin affecting the lamellipodia 
formation and changes in cell morphology with no effect 
on PDGF-BB.
Discussion
In the present report we have provided evidence that the 
direct renin inhibitor, aliskiren, interferes with the SMC 
migration induced by prorenin. Recently, our group has 
demonstrated that PRR mediates the chemotactic effect 
of prorenin on SMCs and this action is mainly mediated 
by the activation of the small GTPases Rac and RhoA.16 
In addition, we and others, have documented that 
aliskiren reduces the PRR expression in vivo and in 
vitro,22,23 which, in turn, determines an inhibitory action 
on PRR activity.22,23 Indeed, the effect of aliskiren on 
PRR expression levels in human SMCs was shown to be 
sufficient to inhibit the transcription of at least three tar-
get genes of prorenin, such as TGF-β, PAI-1, and Type I 
collagen22,23 In the present report, we extend these obser-
vations, reporting the inhibitory effect of aliskiren on 
Rac activation in response to prorenin and SMC migra-
tion. The effect of aliskiren on cell migration was dem-
onstrated by the Boyden’s chamber chemotactic assay 
and confirmed by the real-time monitoring of cell mor-
phology by iCelligence system and the analysis of lamel-
lipodia formation. All these events were shown to be 
significantly inhibited by aliskiren, at the concentration 
of 10−5M, and only when SMCs were stimulated with 
prorenin but not in response to PDGF-BB. Thus, aliskiren 
appears to have a selective action on prorenin-induced 
SMC migration.
Figure 3. Aliskiren does not affect human SMC migration 
in response to PDGF-BB. The experimental conditions are 
the same as in Figure 2. The Boyden’s chamber chemotactic 
assay was performed by using prorenin (10−8M) and PDGF-BB 
(10−9M) as chemotactic agents. †p < 0.05 prorenin and PDGF-
BB vs. basal; *p < 0.05 aliskiren vs. prorenin. The results are 
representative of three independent experiments.
Figure 2. Rac-GTP levels are reduced in human SMCs treated with aliskiren after stimulation with prorenin. Human SMCs were 
cultured for 24 h in Smooth Muscle Cell Growth Medium 2 (50.000 cells per well/48 well tray). After 24 h, medium was changed 
with DMEM/0.4%FCS, ANG (1.5 × 10−7M) in the presence or absence of aliskiren (10−6M, 5 × 10−6M, and 10−5 M). After 24 h, cells 
were stimulated with prorenin (10−8M) for 10 minutes and G-LISA assay for Rac-GTP (a) and RhoA-GTP (b) performed from the 
total protein extracts. Basal indicates cells incubated in DMEM/0.4%FCS and ANG (1.5 × 10−7 M) and not stimulated with prorenin. 
†p < 0.05 prorenin vs. basal; *p < 0.05 aliskiren vs. prorenin. The results are representative of three independent experiments.
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Several lines of evidence indicate that Rac plays an 
important role on SMC migration, associated with the 
development of atherosclerotic plaque, either by inducing 
the lamellipodia formation or by generating reactive oxy-
gen species (ROS) by NADPH oxidase.31,32 Our results 
suggest that the inhibitory effect of aliskiren on Rac activ-
ity may be responsible for the reduction of SMC migra-
tion mediated by prorenin. Indeed, we have previously 
demonstrated that the inhibition of Rac by siRNA com-
pletely abrogated the chemotactic effect of prorenin on 
SMCs.16 Nevertheless, the actual inhibitory mechanism of 
action of aliskiren on Rac activity is still unknown and 
further investigations are required in order to determine if 
aliskiren affects the post-translational modifications of 
Rac, such as geranylgeranylation, or the GDP/GTP 
exchange processes. Indeed, previous studies have estab-
lished the requirement of protein geranylgeranylation of 
the CAAX motif of Rac and RhoA for their interaction 
with the plasma membrane and with the GDP/GTP 
exchange proteins.33–36 In addition, it will be interesting to 
investigate the effect of aliskiren on Rac-mediated ROS 
formation and its contribution on the hypertension-
associated end-organ damage.37 On this matter it is impor-
tant to mention that, recently, aliskiren has been reported 
to reduce vascular NADPH oxidase activity by 41.6% in 
the aortic tissue of ApoE-deficient mice.38 This evidence 
further supports a potential inhibitory effect of aliskiren 
on Rac.
Interestingly, aliskiren does not reduce the intracellular 
levels of RhoA-GTP in SMC stimulated with prorenin. 
The differential action of aliskiren on Rac and RhoA 
could be related to the effect of angiotensin I receptor 
(AT1R) and PRR on the two small GTPases. Indeed, 
while the PRR-mediated activation of both small GTPases 
has only been recently observed by our group,16 the role 
of the AT1 receptor and angiotensin II in vascular SMCs 
is well established.31,39,40 Under our experimental condi-
tions, the addition of prorenin, in the presence of ANG, 
determines a significant increase of angiotensin II forma-
tion,23 and thus the stimulation of both receptors, PRR and 
AT1R. Since aliskiren was shown to fully inhibit the con-
version of ANG to angiotensin I, and only partially 
Figure 4. Effect of aliskiren on lamellipodia formation in human SMCs. Human SMCs were cultured for 24 h in Smooth Muscle Cell 
Growth Medium 2 (40.000 cells per well/24 well tray). After 24 h, media was changed with DMEM/0.4%FCS, ANG (1.5 × 10−7M) in 
the presence or absence of aliskiren (10−5M). After 24 h, cells were stimulated with prorenin (10−8M) and PDGF-BB (10−9M) for 1 h 
then fixed and the cytoskeleton stained with rhodamine–phalloidin. Basal indicates cells incubated in DMEM/0.4%FCS and ANG (1.5 
× 10−7M) and not stimulated with prorenin. Arrows indicate F-actin localization in lamellipodia. Results are representative of three 
independent experiments. The histogram reports the number of cells with lamellipodia counted in three random high-power fields 
(HPFs) from three replicates under high magnification (objective lens 20×). ***p < 0.01; *p < 0.05 prorenin vs. basal; aliskiren vs. 
prorenin. †p < 0.05 prorenin + aliskiren vs. prorenin.
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reducing PRR expression,23 the differential effect on the 
two pathways may account for the selective action on 
Rac.
Our finding on the effect of aliskiren on cell migration, 
although obtained in an in vitro cultured system, may con-
tribute to better understand the pharmacological properties 
of aliskiren. The demonstration that aliskiren can accumu-
late in the arterial wall of the small cortical vessels in the 
kidney,22 suggests a possible inhibition of RAAS in the vas-
culature and PRR expression in vascular SMCs. The rele-
vance of our data are therefore reinforced by these 
observations suggesting a possible in vivo pharmacological 
action of aliskiren on prorenin-mediated SMC migration.
Conclusions
Taken together, in the present study, we have shown that 
aliskiren inhibits prorenin-mediated SMC migration. 
Additional studies are needed to determine the in vivo con-
tribution of this pharmacological action in experimental 
models of cardiovascular diseases.31
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